Evidence map›Paper›PMID 27743175›Full record

ArticleWiener klinische Wochenschrift2017

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm.

Wolfgang Füreder, Sabine Cerny-Reiterer, Wolfgang R Sperr, Leonhard Müllauer, Eva Jäger, Ilse Schwarzinger, Klaus Geissler, Peter Valent

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Wolfgang FürederDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, AKH, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria. wolfgang.fuereder@meduniwien.ac.at.
Sabine Cerny-ReitererDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, AKH, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Wolfgang R SperrDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, AKH, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Leonhard MüllauerDepartment of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
Eva JägerDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Ilse SchwarzingerDepartment of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
Klaus GeisslerDepartment of Internal Medicine V, Hospital Hietzing, Vienna, Austria.
Peter ValentDepartment of Internal Medicine I, Division of Hematology & Hemostaseology, AKH, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Medical University of Vienna · ATKlinik Hietzing · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with aplastic anemia or hypoplastic myelodysplastic syndrome (MDS) may respond to immunosuppressive therapy, including the anti-CD52 antibody alemtuzumab. We analyzed treatment responses to alemtuzumab in 5 patients with MDS or aplastic anemia (AA) evolving to MDS. Two patients with hypoplastic MDS (hMDS) showed a partial response (PR) to alemtuzumab. In both responding patients, a concomitant paroxysmal nocturnal hemoglobinuria (PNH) clone was detected before therapy. One responder relapsed after 15 months and underwent successful allogeneic stem cell transplantation. Both patients are still alive and in remission after 40 and 20 months, respectively. The other patients showed no response to alemtuzumab. One patient died from pneumonia 4 months after treatment. In summary, our data confirm that alemtuzumab is an effective treatment option for a subset of patients with MDS, even in the presence of a PNH clone.

Indexed as

AdultAgedAlemtuzumabAnemia, AplasticAntineoplastic AgentsAntineoplastic Agents, ImmunologicalFemaleHumansLongitudinal StudiesMaleMiddle AgedMyelodysplastic-Myeloproliferative DiseasesTreatment OutcomeAlemtuzumabAntineoplastic AgentsAntineoplastic Agents, ImmunologicalMyelodysplastic syndromeParoxysmal nocturnal hemoglobinuria (PNH)Progenitor cells

Identifiers

PMID27743175
PMCPMC5486731
OpenAlexW2531298600

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.